Hypocholesterolaemic activity of suloctidil: double-blind, crossover short-term and long-term treatment trial.
Two studies were carried out in patients with primary hyperlipidaemia to investigate the effect of suloctidil (200 mg 3-times daily) on serum cholesterol levels and other lipidaemic variables. The first study was a double-blind, crossover comparison of suloctidil and placebo in 23 patients. Patients were allocated at random to receive one or other treatment for 4 weeks, after a wash-out period of 4 weeks on placebo, and were then crossed over to the alternative medication for the following 4 weeks. Patients were kept on a controlled diet throughout the trial. In the second, long-term study, 28 patients were treated, after an initial washout period of 8 weeks on placebo, with suloctidil for periods of up to 1 year. As in the short-term trial, patients were maintained on a controlled diet. The results showed that suloctidil produced a statistically significant reduction in total serum cholesterol and serum triglycerides in the short-term and this reduction was maintained over the longer period of the second study. In addition, there was a concomitant and approximately proportional increase in HDL-cholesterol. Suloctidil was well tolerated and no serious side-effects were reported.
D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D011412:Propanolamines / Q000627:therapeutic use*; D011897:Random Allocation; D013468:Suloctidil / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D011412:Propanolamines; D014280:Triglycerides; D002784:Cholesterol; D013468:Suloctidil